RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participa
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, wil
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall S
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previ
Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operat

6 Beaten Down Stocks Rated Buy (SA Quant)

05:00am, Monday, 19'th Aug 2024
The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE